Low |
您所在的位置:网站首页 › atropine eye drops 001一支能用几次 › Low |
TY - JOUR T1 - Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children T2 - a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)—study protocol AU - Azuara-Blanco, Augusto AU - Logan, Nicola AU - Strang, Niall AU - Saunders, Kathryn AU - Allen, Peter M AU - Weir, Ruth AU - Doherty, Paul AU - Adams, Catherine AU - Gardner, Evie AU - Hogg, Ruth AU - McFarland, Margaret AU - Preston, Jennifer AU - Verghis, Rejina AU - Loughman, James J AU - Flitcroft, Ian AU - Mackey, David A AU - Lee, Samantha Sze-Yee AU - Hammond, Christopher AU - Congdon, Nathan AU - Clarke, Mike N1 - © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. Creative Commons Attribution Non-Commercial License PY - 2020/7 Y1 - 2020/7 N2 - Background/aims: To report the protocol of a trial designed to evaluate the efficacy, safety and mechanism of action of low-dose atropine (0.01%) eye-drops for reducing progression of myopia in UK children. Methods: Multicentre, double-masked, superiority, placebo-controlled, randomised trial. We will enrol children aged 6-12 years with myopia of -0.50 dioptres or worse in both eyes. We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five centres. Participants will instil one drop in each eye every day for 2 years and attend a research centre every 6 months. The vehicle and preservative will be the same in both study arms. The primary outcome is SER of both eyes measured by autorefractor under cycloplegia at 2 years (adjusted for baseline). Secondary outcomes include axial length, best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y) and tolerability at 2 years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body biometry and chorioretinal thickness. Endpoints from both eyes will be pooled in combined analysis using generalised estimating equations to allow for the correlation between eyes within participant. Three years after cessation of treatment, we will also evaluate refractive error and adverse events. Conclusions: The Childhood Atropine for Myopia Progression in the UK study will be the first randomised trial reporting outcomes of low-dose atropine eye-drops for children with myopia in a UK population. AB - Background/aims: To report the protocol of a trial designed to evaluate the efficacy, safety and mechanism of action of low-dose atropine (0.01%) eye-drops for reducing progression of myopia in UK children. Methods: Multicentre, double-masked, superiority, placebo-controlled, randomised trial. We will enrol children aged 6-12 years with myopia of -0.50 dioptres or worse in both eyes. We will recruit 289 participants with an allocation ratio of 2:1 (193 atropine; 96 placebo) from five centres. Participants will instil one drop in each eye every day for 2 years and attend a research centre every 6 months. The vehicle and preservative will be the same in both study arms. The primary outcome is SER of both eyes measured by autorefractor under cycloplegia at 2 years (adjusted for baseline). Secondary outcomes include axial length, best corrected distance visual acuity, near visual acuity, reading speed, pupil diameter, accommodation, adverse event rates and allergic reactions, quality of life (EQ-5D-Y) and tolerability at 2 years. Mechanistic evaluations will include: peripheral axial length, peripheral retinal defocus, anterior chamber depth, iris colour, height and weight, activities questionnaire, ciliary body biometry and chorioretinal thickness. Endpoints from both eyes will be pooled in combined analysis using generalised estimating equations to allow for the correlation between eyes within participant. Three years after cessation of treatment, we will also evaluate refractive error and adverse events. Conclusions: The Childhood Atropine for Myopia Progression in the UK study will be the first randomised trial reporting outcomes of low-dose atropine eye-drops for children with myopia in a UK population. KW - child health (paediatrics) KW - clinical trial KW - drugs KW - optics and refraction KW - treatment medical UR - https://bjo.bmj.com/content/early/2019/10/25/bjophthalmol-2019-314819 UR - http://www.isrctn.com/ISRCTN99883695 UR - http://www.scopus.com/inward/record.url?scp=85074505032&partnerID=8YFLogxK U2 - 10.1136/bjophthalmol-2019-314819 DO - 10.1136/bjophthalmol-2019-314819 M3 - Article SN - 0007-1161 VL - 104 SP - 950 EP - 955 JO - British Journal of Ophthalmology JF - British Journal of Ophthalmology IS - 7 ER - |
CopyRight 2018-2019 办公设备维修网 版权所有 豫ICP备15022753号-3 |